Is RPRX a good stock to buy?
Out of 7 analysts, 5 (71.43%) are recommending RPRX as a Strong Buy, 1 (14.29%) are recommending RPRX as a Buy, 1 (14.29%) are recommending RPRX as a Hold, 0 (0%) are recommending RPRX as a Sell, and 0 (0%) are recommending RPRX as a Strong Sell.
What does Royalty Pharma PLC do?
We collaborate directly with innovators to acquire a new synthetic royalty, monetize an existing royalty or provide capital to an innovator to co-fund clinical development of a product candidate in exchange for a royalty.
Will RPRX Pay a Dividend?
RPRX pays a dividend of $0.72 per share. RPRX’s annual dividend yield is 1.68%. Royalty Pharma’s dividend is higher than the US industry average of 1.4%, and it is lower than the US market average of 3.78%.
How does Royalty Pharma make money?
Royalty Pharma is owned by the billionaire investor Pablo Legorreta – who founded the company in 1996 – and earns revenues either from royalty payment streams it has acquired over the years from other companies, or by investing into development-stage product candidates, in exchange for an agreed amount of post approval …
What is Royalty Pharma’s stock symbol?
What is Royalty Pharma’s stock symbol? Royalty Pharma trades on the NASDAQ under the ticker symbol “RPRX.” Who are Royalty Pharma’s major shareholders?
Where can I buy shares of RPRX?
Shares of RPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What are Wall Street’s price targets for Royalty Pharma’s shares?
3 Wall Street analysts have issued 1-year price targets for Royalty Pharma’s shares. Their forecasts range from $46.00 to $50.00. On average, they expect Royalty Pharma’s share price to reach $48.67 in the next year. This suggests a possible upside of 20.6% from the stock’s current price.
Is there an upside for Royalty Pharma (RPH)?
According to analysts’ consensus price target of $48.67, Royalty Pharma has a forecasted upside of 20.6% from its current price of $40.34. Royalty Pharma has received no research coverage in the past 90 days. Royalty Pharma has received 293 “outperform” votes. (Add your “outperform” vote.) Royalty Pharma has received 132 “underperform” votes.